Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Showing 1 to 25 of 96

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]Technology appraisal guidance
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Aggressive behaviour in people receiving NHS or social careQuality standard
Aggressive behaviour in people receiving NHS or social care: prevention and managementNICE guideline
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Technology appraisal guidanceTBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]Technology appraisal guidanceTBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]Technology appraisal guidanceTBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Technology appraisal guidanceTBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Technology appraisal guidanceTBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Technology appraisal guidanceTBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)Health technology evaluation
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Technology appraisal guidance
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]Technology appraisal guidance
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]Technology appraisal guidance
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]Technology appraisal guidanceTBC
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)NICE guideline
Digital technologies delivering CBT for insomnia in adultsHealth technology evaluation
Digital technologies to support smoking cessation in secondary care patients: early value assessmentHealth technology evaluationTBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All